上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。
MR 409
MR 409 是一种选择性的生长激素释放激素 (GHRH) 激动剂。MR 409 通过增强脑缺血小鼠的内源性神经发生而具有显著的神经保护作用。MR 409 还可以抑制肺癌的体内生长。
MR 409 Chemical Structure
CAS No. : 1445155-39-4
| 规格 |
|
是否有货 |
|
| 100 mg |
|
询价 |
|
| 250 mg |
|
询价 |
|
| 500 mg |
|
询价 |
|
* Please select Quantity before adding items.
| 生物活性 |
MR 409 is a selected growth hormone-releasing hormone (GHRH) agonist. MR 409 has remarkable neuroprotective effects through enhancing endogenous neurogenesis in cerebral ischemic mice. MR 409 also inhibits the in vivo growth of lung cancer[1][2][3][4].
|
体外研究
(In Vitro) |
One week post-myocardial infarction (MI), MR 409 (MR-409) significantly reduces plasma levels of IL-2, IL-6, IL-10 and TNF-α compared to placebo[1].
MR 409 (MR-409; 1 μM) suppresses p53 expression in bovine pulmonary arterial endothelial cells (BPAECs)[2].
MR 409 (1 μM) induces the activation of JAK2, STAT3 and ERK1/2[2].
MR 409 (MR-409; 1 and 5 μM) decreases LPS-induced PGE2 and 8-iso-PGF2α levels, in a dose-dependent manner[3].
MR 409 (1 and 5μM) decreases LPS-induced lactate dehydrogenase (LDH) activity and nitrite production, without showing a dose-dependent effect[3].
MR 409 (1 and 5 μM) decreases LPS-induced gene expression of COX-2, NF-κB and iNOS in colon specimens, without a dose-dependent effect[3].
MR 409 (MR-409) can stimulate endogenous neurogenesis and improve the tMCAO-induced loss of neuroplasticity. MR 409 also enhances the proliferation and inhibits apoptosis of neural stem cells treated with oxygen and glucose deprivation-reperfusion[4].
Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.
Western Blot Analysis[2]
| Cell Line: |
BPAEC |
| Concentration: |
1 μM |
| Incubation Time: |
24, 48 and 72 hours |
| Result: |
Significantly suppressed p53 expression levels after 48 and 72 hours of treatment. |
|
体内研究
(In Vivo) |
MR 409 (MR-409) inhibits the in vivo growth of lung cancer xenografted into nude mice[3].
MR 409 (5 μg; s.c. treated daily for 4 weeks) reduces nociceptive response in mice[3].
Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.
| Animal Model: |
Adult C57/BL6 male mice (5 weeks old, weight 20-22 g)[3] |
| Dosage: |
5 µg |
| Administration: |
Treated daily by subcutaneous (s.c.) administration of 0.1 mL solution |
| Result: |
Showed maximal antinociceptive effects at 2 weeks. Sustained a moderate analgesic effect at 4 weeks. |
|
| 分子量 |
|
| Formula |
|
| CAS 号 |
|
| Sequence Shortening |
{N-Me}-Y-{D-Ala}-DAIFTNSYR-{Orn}-VL-{Abu}-QLSAR-{Orn}-LLQDI-{Nle}-DR-NHMe
|
| 运输条件 |
Room temperature in continental US; may vary elsewhere.
|
| 储存方式 |
Please store the product under the recommended conditions in the Certificate of Analysis.
|
| 参考文献 |
-
[1]. Rosemeire M Kanashiro-Takeuchi, et al. New therapeutic approach to heart failure due to myocardial infarction based on targeting growth hormone-releasing hormone receptor. Oncotarget. 2015;6(12):9728-39.
[2]. Mohammad A Uddin, et al. GHRH antagonists support lung endothelial barrier function. Tissue Barriers. 2019;7(4):1669989.
[3]. Lucia Recinella, et al. Protective effects of growth hormone-releasing hormone analogs in DSS-induced colitis in mice. Sci Rep. 2021 Jan 28;11(1):2530.
[4]. Yueyang Liu, et al. Agonistic analog of growth hormone-releasing hormone promotes neurofunctional recovery and neural regeneration in ischemic stroke. Proc Natl Acad Sci U S A. 2021 Nov 23;118(47):e2109600118.
|
所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务
